"label","name","id","text","instanceType","description","uuid:ID"
"","OBJ1","Objective_1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective","Main objective","90a550fc-0a05-4ec0-a158-77cfa8e1c100"
"","OBJ2","Objective_2","To document the safety profile of the xanomeline TTS.","Objective","Safety","37898446-a37a-45df-8a80-0d66a846226e"
"","OBJ3","Objective_3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective","Behaviour","61e0c148-9560-49f2-83fd-cddfa0528269"
"","OBJ4","Objective_4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective","","3e092b96-96b7-4132-8e9f-6b628a9ac959"
"","OBJ5","Objective_5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective","","81b96cf3-f3a4-4734-87b5-84966fa2aaff"
"","OBJ6","Objective_6","To assess the treatment response as a function of Apo E genotype.","Objective","","5e2c9d23-4f7c-4929-9b19-3cf43af53afe"
